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Summary.-The gross response of a transplantable fibrosarcoma (RIB5) in rats
treated with a single dose of 10,50, 100 or200 mg/kg body weight of cyclophosphamide
(CP) is reported. The variation in mitotic and tritiated thymidine (3H-TdR) label-
ling indices after a single dose of 100 mg/kg CP was studied. Examination of
chromosome spreads has shown the time course of the visible damage to DNA
caused by CP and a transient arrest of cells in G2 was demonstrated by micro-
densitometry. The effects of 100 mg/kg body weight CP given in 2 equal doses
separated by various time intervals were examined in an attempt to relate tumour
response to its altered cellular state at the time of the second dose.
AN understanding of the kinetics of
tumour cell proliferation after therapy is
essential if efficacious treatment schedules
are to be designed on a rational basis.
Regrowth of transplanted tumours
following irradiation or chemotherapy
has been studied frequently, but many
of the investigations were confined to
ascitic tumours or leukaemias where
analysis of tumour cell survival is rela-
tively easy. In some cases, e.g. mice
with L1210 leukaemia given cyclophos-
phamide, such studies have led to effective
treatment schedules (Skipper, 1965).
Quantitative investigations on the re-
growth of solid tumours are more difficult
because it is not as easy to estimate cell
survival in a solid tumour as it is in an
ascitic tumour or leukaemia. Rheinhold
(1965) has developed a method of pre-
paring cell suspensions from solid tumours
which Barendsen and Broerse (1969, 1970)
and van Putten and Lelieveld (1970) have
used to investigate tumour proliferation
after irradiation or chemotherapy. Such
investigations can be accompanied by
problems such as the survival fraction
measured varying with the time after
treatment chosen to perform the assay,
and also that the cloning efficiency may
not be very high.
Others have followed tumour response
to therapy by measuring changes in
overall size (Thomlinson, 1960; Thomlin-
son and Craddock, 1967; Skipper, 1967;
Suntyeff and Luse, 1970). However, size
changes reflect the interplay of such
factors as the rate of tumour cell pro-
duction, cell death, stromal proliferation,
reabsorption of material and oedema.
This paper describes the gross response
of a solid tumour to cyclophosphamide
and a more detailed analysis of the
perturbations of cellular proliferation.
The response of the tumour to a second
dose ofcyclophosphamide was also studied
in an attempt to relate this response to
the proliferative state of the tumour after
the first dose of the drug.
MATERIALS AND METHODS
A transplantable rat fibrosarcoma (RIB5),
originally benzpyrene induced in 1945 in
inbred Wistar rats, was maintained routinely
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by subcutaneous grafts in this strain. Rats
w,ere fed Oxoid 41B and given water ad
libitum. For the work described in this
paper the tumour was transplanted subcu-
taneously into rats (60-110 g) using the
method of Thomlinson (1960) which ensured
that the tumours grew as discrete encapsul-
ated spheres. Mean tumour diameter was
calculated from 3 diameters measured at
least 5 times per week. Tumours whose 3
measured diameters differed by more than
3 mm were excluded from experiments.
Tumours were treated when their mean
diameter was between 8-10 mm (T size);
this size was reached 10-30 days after
transplantation. As tumours reached T size
they were allotted randomly to control and
experimental groups. Intraperitoneal injec-
tions ofcyclophosphamide (Endoxana; Ward,
Blenkinsop & Co. Ltd, Wembley) (CP) were
given between 9 and 11 a.m. at doses
indicated in each experiment.
Mitotic and tritiated thymidine (3H-TdR)
labelling indices
As the distribution of mitoses and labelled
cells throughout the solid tumour is uneven,
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mitotic and 3H-TdR indices were counted
on smears of tumour cells. Slices oftumour,
approximately 1-2 mm thick, were taken
across a diameter of the tumour and were
minced with scissors to produce a cell
suspension. To study the mitotic index the
cell suspension was smeared on slides, fixed
in methanol and stained with Giemsa and
at least 4000 cells were counted.
For the studies of labelling index,
3H-TdR, specific activity 5 Ci/mol/l (Radio-
chemical Centre, Amersham, England) was
given by intraperitoneal injection at a dose
of 1 ytCi/g body weight, between 10 and
11 a.m., one hour before killing the animals.
Autoradiographs of tumour smears were
prepared by dipping in Ilford K5 Nuclear
Emulsion, diluted 2: 1 with water and
exposed for 56 days at 4°C; they were then
developed in Kodak D19 developer, fixed
in Johnson's Fixsol and stained with a
modified Harris's haematoxylin. At least
1000 cells were counted to determine the
labelling index.
Karyological study
Chromosome preparations were made by
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FIG. 1. Growth curve of tumour RIB5 after cyclophosphamide. Each point represents the mean
tumour diameter for a group (n) as detailed in Table I, of female and male animals and
standard errors greater than 1 mm are shown. ....* Control; *- -. 10 mg/kg CP; _ 50 mg/kg CP; * -* 100 mg/kg CP; * 200 mg/kg CP (y only).
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TABLE I.-The Rate, of Growth of Tumours from 10 mm to 20 mm and from 20 mm to
30 mm in Diameter
Time in days taken to grow from
Treatment
(mg/kg CP)
Control 1
*Control 2
10
50
100
t200
2x50
2x50
2x50
2x50
Time of
treatment
Day T
Day T
Day T
Day T
Day T and day T+1
Day T and day T+2
Day T and day T+3
Day T and day T+7
_
10-20 mm diameter
Mean SE n
3 9 0-1 22
4*1 0-2 19
5 3 0 3 9
6 6 0-4 19
10 6 0 9 20
14 7 0 6 6
9-4 1.1 9
8 7 0 6 18
8 8 0 7 18
6 6 0*9 9
20-30 mm diameter
Mean SE n
3-5 0-2 19
3.5 041 19
3 6 0 3 9
4.3 0 3 14
4 3 0 3 11
4 7 0 5 6
5 8 0 9 6
6 4 0 5 15
6*3 0 4 15
7 8 1.1 6
* End of serial transplantation series.
t Female rats only.
SE = Standard Error; n = number of animals.
the method of Moorhead et al. (1960) and
examined for abnormalities such as described
by Vrba (1967).
Distribution of cells within the cell cycle
The relationship of DNA content to
DNA synthesis in tumour cells from CP
treated and control rats was studied using
the photographic mapping technique de-
scribed by Cooper et al. (1966). DNA was
stained by the Feulgen method with 45 min
hydrolysis in 5N HCI at 20°C to give maximal
staining of interphase cells, and measured
with a Deeley pattern microspectrophoto-
meter (Barr & Stroud Ltd, Glasgow).
RESULTS
Tumour growth
Tumour growth was rapid and un-
treated tumours grew from 10 to 20 mm
in diameter in about 4 days (Fig. 1).
The initial volume doubling time was
about 24 hours and this is in agreement
with the findings of Thomlinson and
Craddock (1967). There was no detect-
able difference between the growth rate
of tumours in male and female animals
nor between tumours grown in adult and
young rats. The growth of tumours in
untreated rats was the same at the
beginning of this series of experiments
and at the end 12 months later, during
which time the tumours had undergone
approximately 30 routine transplant pas-
sages (Table I).
The effects of various single doses of
cyclophosphamide (CP) given to the rats
when the tumours were 8-10 mm in
diameter (T size), are shown in Fig. 1.
Although CP caused an inhibition of the
growth rate of the tumours, doses up to
200 mg/kg failed to cause tumour regres-
sion. The extent of the delay in tumour
growth produced by various doses of CP
is shown in Table I. The sex of the
host did not make any significant differ-
ence to tumour growth after CP treat-
ment. However, it was found that
tumour-bearing males were killed by a
dose of 200 mg/kg whilst all the females
survived this dose, hence all the 200 mg/kg
data are from female rats only.
Thomlinson and Craddock (1967) in
their studies of the radiosensitivity of
this tumour showed that the rate of
growth of treated tumours after they
had reached a diameter of 20 mm was
not the same as that ofuntreated controls.
Therefore the times taken for tumours to
grow from T size to 20 mm in diameter
and from 20 mm to 30 mm in diameter
have been calculated for control and
treated animals. Table I shows that the
growth of the tumour from 10-20 mm
after 10 mg/kg CP is significantly slower
than in the controls (P < 01%) but the
306THE EFFECT OF CYCLOPHOSPHAMIDE
subsequent growth rate from 20 to
30 mm was normal. After larger doses
of CP the initial tumour growth was
increasingly delayed and the time taken
for tumours to grow from 20-30 mm in
diameter was significantly longer than
the time taken by tumours from untreated
animals.
When tumours that had regrown
after treatment with 100 mg/kg CP were
transplanted into new hosts, their growth
rates were found to be identical to that in
the controls.
The effect on tumour growth rate of
giving a total of 100 mg/kg CP in 2
doses of 50 mg/kg with varying time
intervals between the doses is shown in
Table I. Dividing the dose did not
increase the time taken for the tumours
to grow from 10 to 30 mm in diameter.
The initial growth rate of the tumour
from 10 to 20 mm in diameter appeared
faster when the 100 mg/kg of CP was
given in 2 doses but this was compen-
sated for by a slower growth rate between
20 and 30 mm in diameter. The fastest
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Fia. 2.-(a) Mitoses per 1000 tumour cells in untreated tumours 0 *, and for tumours
from rats given 100 mg/kg CP at T size A - - -A; (b) the percentage of abnormal tumour
chromosome spreads seen after 100 mg/kg CP A- - - -A (abnormalities in untreated control
tumours were below 1%); (c) the number of cells labelled with 3H-TdR per 100 tumour cells
in untreated tumours ,._,, and for tumours from rats given 100 mg/kg CP at T size
A--- -A. Means and standard errors of 4 animals at each point are shown.
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initial growth rate (10-20 mm) was seen
when the 2 doses were separated by 7
days. This was the same initial growth
rate as that observed after a single
50 mg/kg dose because, as shown in
Fig. 1 , such tumours had
reached 20 mm in diameter by the time
the second dose was given (T + 7).
Tumour cell proliferation
Mitotic indices, determined on smear
preparations of tumour cell suspensions,
were obtained 0*5, 1, 2, 3, and 7 days
after the host had been given 100 mg/kg
body weight of CP and from untreated
tumours at the same time intervals after
T size. It can be seen (Fig. 2(a)) that
following treatment with CP there was
an initial depression of the mitotic index
which was followed by a rapid rise to 2
to 3 times the control value at 2 days.
This high value was maintained on the
third day, but had returned to normal
7 days after injecting the CP. Examina-
tion of the mitotic figures in the smears
showed that 2 and 3 days after treatment
only 27 and 38% respectively were
normal. Abnormalities such as chromo-
somes unattached to the mitotic spindle
and varying degrees of fragmentation
were seen.
In order to see in greater detail the
extent ofchromosome damage, karyotypic
analyses were made on 4 tumours at
each time interval after CP and 50
chromosome spreads scored for the pre-
sense of chromatid breaks and abnormal
reunion figures associated with damage
by this alkylating agent; these spreads
could not show abnormalities such as
failure to attach to the spindle. It was
observed (Fig. 2(b)) that though the peak
frequency for abnormal mitotic figures
occurred one day after treatment at a
time when the mitotic index was still low,
abnormalities could still be detected in
40% of the chromosome spreads made on
the second day after treatment when the
mitotic index had reached its peak value.
One week after treatment only 8% of
the tumour mitoses were considered to
be abnormal. In control tumours from
untreated rats, fewer than 1% of chromo-
some spreads showed comparable abnor-
malities.
Examination of the distribution of
chromosome number in 4 tumours which
had been transplanted after treatment
with cyclophosphamide and had regrown
at the control rates showed that a small
change in the modal chromosome number
had occurred. Fig. 3 shows the wide
distribution of chromosome number in
the untreated tumours about the mode
of 65-5 (SE + 1-6) and the distribution
of chromosome number of one of the CP
treated tumours which had regrown
after transplantation (Mode 62.9 SE+0.4).
3H-TdR labelling studies
As a further indication of the pro-
liferative activity of the tumour following
treatment with CP the 3H-TdR labelling
indices in the tumours 0 5, 1, 2, 3 and 7
days after treatment with CP (100 mg/kg
body weight) and matched controls were
examined (Fig. 2(c)). The only signifi-
cant difference between the control and
treated animals was the increase of
labelling index 12 hours after treatment.
In order to examine the distribution
of tumour cells within the cell cycle
0.5, 1, 2, 3 and 7 days after CP and in
the appropriate controls the DNA content
of 100 cells per tumour was measured.
Smears from 2 control and usually 3
experimental tumours were examined at
each time interval. After measuring the
DNA content the cello labelled with
3H-TdR were identified by autoradio-
graphy and the results are represented in
Fig. 4. The DNA content of small
lymphocytes in each tumour smear was
used to establish the 2C mode. All
tumours contained connective tissue cells
with DNA content about the 2C mode.
In control tumours 0.5, 1 and 2 days
after T size, there was a clear cut G.
mode with a DNA content of approxi-
mately 4C. There were a few cells labelled
with 3H-TdR with DNA content between
the 4 and 8C values and cells with G2
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FIG. 3. Histogram of the distribution of chromosome number in (a) an untreated RIB.5
tumour; (b) a CP treated tumour which had regrown after transplantation to an untreated
host.
DNA content were infrequent (Fig. 4(a)).
Control tumours, 3 and 7 days after
T size showed a slight increase in the
number of cells with G2 DNA content
(Fig. 4(b)).
Twelve hours after CP, although there
was variation amongst the 3 tumours
studied, there was a decrease in the
number of cells in the G1 mode and a
build-up of cells with higher DNA content,
the majority of which were labelled with
3H-TdR (Fig. 4(c)). Twelve hours later
(Fig. 4(d)) this build up of cells with
higher DNA values had continued so that
the G2 mode was more pronounced than
the GQ mode; a moderate proportion of
the cells with high DNA values were
labelled. Two days after CP (Fig. 4(e)),
the number of cells at the G2 mode was
still higher than in controls (Fig. 4(a))
but the pattern of labelling appeared to
be normal. Fig. 4(f) shows that 3 days
after the drug the G1 peak had returned
but was not as prominent as in the appro-
priate controls (Fig. 4(b)) and the build
up of cells in G2, evident 1 and 2 days
after CP, was no longer so marked.
Seven days after CP the normal distribu-
tion of cells was restored (Fig. 4(g)).
DISCUSSION
Cyclophosphamide in doses 10, 50 and
100 mg/kg retarded the growth of the
RIB5 fibrosarcoma. In this series of
experiments maximum delay of tumour
growth was produced by a dose of 200
mg/kg in females, but this dose was
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lethal to tumour bearing males though
males without tumours were able to
tolerate this dose level. Cyclophosphamide
did not make the tumours decrease in
diameter. This contrasts with Thomlin-
son's observation (Thomlinson, 1960) that
a single dose of 4000 rad of x-rays given
to the tumours of rats breathing air
produced tumour regression, but in these
circumstances tumour growth rate was
slower than we observed after cyclo-
phosphamide treatment.
As the rate of tumour growth after
treatment was not uniform regrowth has
been divided into two arbitrary periods
of 0 to 20 mm and 20 to 30 mm in
diameter in a way similar to Thomlinson's
analysis of this tumour's response to
irradiation. The time taken for tumour
growth from 20-30 mm after 10 mg/kg
CP was the same as control tumours, but
after higher doses of CP, growth from
20-30 mm in diameter was significantly
delayed. This slow growth rate was
probably due to the effects of CP on the
tumour micro-architecture and to its
residual systemic effects because when
CP treated tumours were transplanted to
untreated rats, tumour growth was the
same as control growth even though the
CP treated tumours showed a slight shift
in modal chromosome number.
Measurements of gross size provide
limited information about a tumour be-
cause of the many factors involved and
more detailed information on the pro-
liferative state of the tumour has been
sought. These investigations have been
done on smears made from minced
tumour. The advantages of analysing
smear preparations are the relative rapi-
dity of the study and the fact that pooling
the cells from a slice of the tumour over-
comes the sampling problems encountered
in sections of heterogeneous specimens
(Simpson-Herren, Blow and Brown, 1.968;
Mendelsohn and Shackney, 1970).
Following a single dose of 100 mg/kg
of CP the cytokinetic disturbances ob-
served can be described as follows: by
12 hours after treatment, the 3H-TdR
labelling index was almost doubled (Fig.
2(c)), and was associated with a decrease
in the flow of cells into mitosis, as shown
by the low mitotic index at this time
(Fig. 2(a)). One day after CP the mitotic
index had remained low and the DNA
distribution analyses (Fig. 4(d)), showed
that this was accompanied by a build up
of cells in G2 and by the return of the
3H-TdR labelling index to within normal
limits (Fig. 2(c)). Twenty-four hours
later the mitotic index had risen rapidly
despite the build-up of cells still evident
in G2 and, probably as a result, GQ
cells were increasing in number, as shown
by the return of the G1 mode (Fig. 4(e)).
Three days after CP the mitotic index of
the tumour was still raised but fewer of
these mitoses were abnormal than one
and 2 days previously (Fig. 2(b)). The
DNA study showed that at this time the
build up of cells in G2 was no longer
marked. By 7 days after CP all the
parameters investigated were normal.
Alkylating agents have been observed
to depress mitotic activity rapidly (Layde
and Baserga, 1964; Fox and Fox, 1967;
DeCosse and Gelfant, l970). Of these
authors only Fox and Fox noted that
the initial depression was followed, in
their case of P388 cells treated in vitro
with methyl methanesulphonate, by an
increase in mitotic activity to 2100o of
the control values. In our investigation
the high mitotic activity was probably not
contributing effectively to tumour repopu-
lation because detailed examination of
chromosome spreads, one and 2 days
after treatment, showed that many had
abnormal chromosomes. This wave of
abnormality disappeared by the end of
the first week after treatment. The
majority of chromosome spreads seen
12 hours after CP were normal. This
observation fits well with the fact that
the cell cycle of this tumour is 13*2 + 1-0
hours (Denekamp, 1970) and that the
damage to the DNA produced by alkylat-
ing agents such as CP is only visible at
the second division after alkylation (Love-
less, 1966).
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The reason for the high 3H-TdR
labelling index 12 hours after treatment
is of some interest. This may well be
due to the fact that the S period has
been prolonged, although Young and
DeVita (1970) suggested that CP, unlike
1,3-bis(2-chloroethyl)-l-nitrosourea, did
not prolong the S period of L1210
leukaemia cells growing in an ascitic
form. In our own experiments the label-
ling intensity of cells at 12 hours after
CP was not less than that in the controls
suggesting that the rate of DNA synthesis
was not appreciably slower.
The DNA measurements (Fig. 4(c))
show that the majority of the labelled
cells do have a DNA content above the
G1 value but the technique does not
show whether the DNA synthesis is for
repair or semi-conservative replication.
The time scale of repair after alkylating
agents is probably different from that
after irradiation (Painter, 1970; Fox and
Ayad, 1971) and repair may not be
complete by 12 hours. Repair synthesis
has been demonstrated by autoradio-
graphy (Fox and Ayad, 1971) but these
workers used hydroxyurea to block semi-
conservative DNA synthesis before detect-
ing repair synthesis. It is not known
whether cells can repair DNA during
all parts of the cell cycle or whether this
is restricted to the S phase (Painter,
1970; Fox and Ayad, 1971). An alterna-
tive explanation could be that there was
a recruitment of cells into S from an
" out of cycle " population. However,
as the majority of the progeny of these
cells had grossly abnormal chromosomes
12 hours later it is unlikely that many
of them would contribute to the subse-
quent growth of the tumour.
Kinetic analyses to determine cell
cycle time such as the percentage labelled
mitoses method of Quastler and Sherman
(1959) are not valid in the perturbed
state that exists in a tumour in the first
few days after treatment of the host with
a cytotoxic drug. The method can be
adapted to follow the flow of cells from
G1 and G2 to mitosis in the initial hours
after treatment. Estimates of the flow
of cells into mitosis at later times after
treatment are difficult to obtain; e.g. the
colchicine accumulation technique is not
reliable when cells have been damaged by
the treatment (unpublished observation
on accumulation of mitoses after CP).
There are therefore limitations in the
methods one can use to estimate the
length of time cells spend in transit
through the phases of the cell cycle.
An indication of the length of time
cells spend in G1, S and G2 can be obtained
from the relative proportions of cells in
these phases. In a control tumour (Fig.
4(a)), the G2 phase appeared short in
comparison with S and G1. This con-
trasted with tumours one and 2 days after
CP (Fig. 4 (d), (e)), where the length of
time cells spent in G2 appeared to have
increased.
Interpreting DNA histogram data in
this way is not always straightforward.
It has been discussed previously that the
increase in the number of cells apparently
in S 12 hours after CP (Fig. 4(c)), does
not necessarily mean that the S period
has been lengthened. Control RIB5 tu-
mours at T size have an appreciable out
of cycle population and the most accurate
estimate of the size of the growth fraction
of the tumour has been suggested to be
450o (Denekamp, 1970). This means that
the proportion of time cells spend in the
phases of the cell cycle is only propor-
tional to the number of cells detected in
those phases by their DNA contents if
one subtracts the " out of cycle " cells
from the total number of cells. In
control RIB5 tumours we have shown
(unpublished observation) that the out
of cycle cells have G1 DNA contents but
the fate and the DNA content of the
" out of cycle" cell after CP treatment
is unknown. This means that accurate
estimates of the length of the G1, S and
G2 phases in the CP treated tumours from
the proportions of cells in these phases
are not possible. Nevertheless the marked
changes in the distribution of DNA
content after CP indicates the disturbances
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in the cellular kinetics as a result of the
drug and one can observe when these
disturbances are resolved.
It has often been stated (e.g. in
Symposium on a Critical Evaluation of
Cancer Chemotherapy, 1969) that a better
understanding of the kinetics of tumour
populatior.s is necessary for more effective
chemotherapy. One purpose of these
experiments was to discover whether
knowledge of the reaction of a tumour to
cyclophosphamide could be used as a
basis for the design of a rational multiple
dose therapy. Dose schedules which use
CP to cure certain animal tumours have
been devised (Griswold et al., 1968;
Laster et al., 1969; Teller, Bowie and
Stock, 1970). In man CP is probably
the most widely used alkylating agent in
the treatment of late breast cancer where
the clinical problems involved in finding
optimal dose schedules are considerable
(Stoll, 1970).
In our experiments tumour growth
was compared in rats given 100 mg/kg
body weight of CP in a single dose and
two 50 mg/kg body weight doses separated
by one, 2, 3 or 7 days. Dividing the
dose did not delay overall tumour growth
(10-30 mm); initial growth from 10-20 mm
in diameter was faster than in rats given
a single dose of 100 mg/kg but this was
associated with slower growth from 20-30
mm in diameter. Varying the time of
the second dose of CP was part of an
attempt to compare tumour growth rate
with the disturbances in the tumour cell
population at the time of the second dose.
However, Table I shows that despite the
differences in the tumour cell populations
one, 2 and 3 days after a dose of CP
there were no significant differences in
tumour growth rate when the second
dose was given at these times.
It has been shown how the pattern
of proliferative behaviour of the tumour
changes rapidly as the result of treatment
with an alkylating agent and biopsies at
a single point of time from a treated
tumour could, in the absence of informa-
tion relating to the whole sequence of
change, lead to misinterpretations of
what was really happening. Although
normal mitoses were seen 2 days after
CP the distribution of cells within the
phases of the cell cycle, as shown by
DNA measurements (Fig. 4) had not
returned to normal by 3 days. One
does not know if these cells with normal
mitoses are clonogenic nor is an assay
available to test their clonogenicity in
vitro or on transplantation. It is, how-
ever, cell survival in situ which is impor-
tant in therapy where tumour blood
supply, immune mechanisms, availability
of metabolites and accumulation of waste
products are all involved in cell survival.
In order to try to assess the nature
ofthe overall change in situ morphometric
studies have been made analysing the
relationship of the malignant cells to the
other parts of the tumour from control
and CP treated animals and these results
will be reported in a sequel to this paper.
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